Sol-Gel Technologies (SLGL) Common Equity (2016 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Common Equity came in at $51.4 million in Q1 2026, up 154.84% year-on-year from $20.2 million in Q1 2025, and up 125.36% on a QoQ basis from $22.8 million in Q4 2025.
Sol-Gel Technologies (SLGL) Common Equity (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Common Equity data on file, last reported at $51.4 million in Q1 2026.
- On a quarterly basis, Common Equity rose 154.84% year-over-year to $51.4 million in Q1 2026; TTM through Mar 2026 was $51.4 million, a 154.84% increase from a year earlier, with the FY2025 full-year figure at $22.8 million, down 20.93% from the prior year.
- Common Equity for Q1 2026 stood at $51.4 million, up from $22.8 million in the prior quarter.
- Over the last five years, Common Equity for SLGL reached as high as $51.4 million in Q1 2026 and fell as low as $20.2 million in Q1 2025.
- Historically, Common Equity has averaged $38.1 million across 5 years, with a median of $38.6 million in 2023.
- Across the five-year window, Common Equity slumped 38.22% in 2025 and soared 154.84% in 2026, its largest moves.
- Year by year, Common Equity stood at $42.2 million in 2022, then dropped by 8.45% to $38.6 million in 2023, then dropped by 25.34% to $28.8 million in 2024, then declined by 20.93% to $22.8 million in 2025, then jumped by 125.36% to $51.4 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $51.4 million in Q1 2026, $22.8 million in Q4 2025, and $26.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Sol-Gel Technologies | 227.58 Mn | 217.44 Mn | - | 51.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.41 Mn |
| Dec 31, 2025 | 22.81 Mn |
| Sep 30, 2025 | 26.03 Mn |
| Jun 30, 2025 | 31.88 Mn |
| Mar 31, 2025 | 20.17 Mn |
| Dec 31, 2024 | 28.85 Mn |
| Sep 30, 2024 | 34.71 Mn |
| Jun 30, 2024 | 34.90 Mn |
| Mar 31, 2024 | 32.65 Mn |
| Dec 31, 2023 | 38.64 Mn |
| Sep 30, 2023 | 43.13 Mn |
| Jun 30, 2023 | 48.30 Mn |
| Mar 31, 2023 | 44.06 Mn |
| Dec 31, 2022 | 42.21 Mn |
| Sep 30, 2022 | 47.47 Mn |
| Jun 30, 2022 | 50.35 Mn |
| Mar 31, 2022 | 50.12 Mn |
| Dec 31, 2021 | 55.59 Mn |
| Sep 30, 2021 | 41.44 Mn |
| Jun 30, 2021 | 39.25 Mn |